• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
PENG Lin, YU Xiao, CAI Yanfei, JIN Jian, LI Huazhong. Research advances of recombinant coagulation factor VII expression and synthesizing mechanism[J]. Journal of China Pharmaceutical University, 2015, 46(5): 623-628. DOI: 10.11665/j.issn.1000-5048.20150518
Citation: PENG Lin, YU Xiao, CAI Yanfei, JIN Jian, LI Huazhong. Research advances of recombinant coagulation factor VII expression and synthesizing mechanism[J]. Journal of China Pharmaceutical University, 2015, 46(5): 623-628. DOI: 10.11665/j.issn.1000-5048.20150518
shu

Research advances of recombinant coagulation factor VII expression and synthesizing mechanism

More Information
    Graphical Abstract
    • Abstract
  • Haemophilia is caused by lack of coagulation factor VIII or IX in patients′ blood with inadequate hemostasis. Currently recombinant coagulation factor VII(rFVII)produced in different cells is used against clinical bleeding of haemophilia patients. To enhance the production and activity of rFVII, some eukaryotic cells such as baby hamster kidney(BHK), Chinese hamster ovary(CHO), insect cell and fish embryo, were used to express rFVII. Meanwhile, the effect of functional gene on the activity of rFVII and the limitation of rFVII production caused by post-translational modification were investigated by different methods. The role of rFVII in hemostasis, synthesis of rFVII in different eukaryotic cells and impact on production of post-translational modification are reviewed in this article.
    • FullText(HTML)
    • References (37)
  • [1]
    Davie EW,Ratnoff OD.Waterfall sequence for intrinsic blood clotting[J].Science,1964,145(3638):1310-1312.
    [2]
    Hoffman M,Pawlinski R.Hemostasis:old system,new players,new directions[J].Thromb Res,2014,133(Suppl 1):S1-S2.
    [3]
    Repke D,Gemmell CH,Guha A,et al.Hemophilia as a defect of the tissue factor pathway of blood coagulation:effect of factors VIII and IX on factor X activation in a continuous-flow reactor[J].PNAS,1990,87(19):7623-7627.
    [4]
    Roberts HR,Monroe DM,Escobar MA.Current concepts of hemostasis-implications for therapy[J].Anesthesiology,2004,100(3):722-730.
    [5]
    Dijk K,Fischer K,Bom JG,et al.Variability in clinical phenotype of severe haemophilia:the role of the first joint bleed[J].Haemophilia,2005,11(5):438-443.
    [6]
    Hedner U,Lee C.First 20 years with recombinant FVIIa(Novo-Seven)[J].Haemophilia,2011,17(1):172-182.
    [7]
    Coppola A, Di Capua M, Di Minno MND,et al.Treatment of hemophilia:a review of current advances and ongoing issues[J].J Blood Med,2010,1:183-195.
    [8]
    Nilsson I,Hedner U,Björlin G.Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide[J].Ann Intern Med,1973,78(1):91-95.
    [9]
    Hedner U,Nilsson I,Bergentz S.Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo[J].Thromb Haemost,1976,35(2):386-395.
    [10]
    Hedner U, Nilsson I, Bergentz S. Studies on the thrombogenic activities in two prothrombin complex concentrates[J].Thromb Haemost,1979,42(3):1022-1032.
    [11]
    Osterud B,Miller-Andersson M,Abildgaard U,et al.The effect of antithrombin III on the activity of the coagulation factors VII,IX and X[J].Thromb Haemost,1976,35(2):295-304.
    [12]
    Hedner U,Glazer S,Pingel K,et al.Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy[J].Lancet,1988,2(8621):1193.
    [13]
    Lusher J,Ingerslev J,Roberts H,et al.Clinical experience with recombinant factor VIIa[J].Blood Coagul Fibrinolysis,1998,9(2):119-128.
    [14]
    Monroe DM,Hoffman M,Oliver JA,et al.Platelet activity of high-dose factor VIIa is independent of tissue factor[J].Br J Haematol,1997,99(3):542-547.
    [15]
    Hedner U.FactorVIIa and its potential therapeutic use in bleeding-associated pathologies[J].Thromb Haemost,2008,100(4):557-562.
    [16]
    Hoffman M.A cell-based model of coagulation and the role of factor VIIa[J].Blood Rev,2003,17(Suppl 1):S1-S5.
    [17]
    Lisman T,Mosnier LO,Lambert T,et al.Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A[J].Blood,2002,99(1):175-179.
    [18]
    He S,Blomback M,Ekman BG,et al.The role of recombinant factor VIIa(FVIIa)in fibrin structure in the absence of FVIII/FIX[J].J Thromb Haemost,2003,1(6):1215-1219.
    [19]
    Hagen FS,Gray CL,O′Hara P,et al.Characterization of a cDNA coding for human factor VII[J].PNAS,1986,83(8):2412-2416.
    [20]
    Berkner K,Busby S,Davie E,et al.Isolation and expression of cDNAs encoding human factor VII[J].Cold Spring Harb Symp Quant Biol,1986,51:531-541.
    [21]
    Jurlander B,Thim L,Klausen NK,et al.Recombinant activated factor VII(rFVIIa):characterization,manufacturing,and clinical development[J].Semin Thromb Hemost,2001,27(4):373-383.
    [22]
    Hedner U,Ljundberg J,Lund-Hansen T.Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model[J].Blood Coagul Fibrinolysis,1990,1(2):145-151.
    [23]
    Omasa T,Onitsuka M,Kim WD.Cell engineering and cultivation of Chinese hamster ovary(CHO)cells[J].Curr Pharm Biotechnol,2010,11(3):233-240.
    [24]
    Kim JY,Kim YG,Lee GM.CHO cells in biotechnology for production of recombinant proteins:current state and further potential[J].Appl Microbiol Biotechnol,2012,93(3):917-930.
    [25]
    Berkner KL.Expression of recombinant vitamin-k-dependent proteins in mammalian-cells factor-IX and factor-VII[J].Methods Enzymol,1993,222:450-477.
    [26]
    Kemball-Cook G,Garner I,Imanaka Y,et al.High-level production of human blood-coagulation factor-VII and factor-XI using a new mammalian expression vector[J].Gene,1994,139(2):275-279.
    [27]
    Kazama Y,Hamamoto T,Foster DC,et al.Hepsin,a putative membrane-associated serine-protease,activates human factor-VII and initiates a pathway of blood-coagulation on the cell-surface leading to thrombin formation[J].J Biol Chem,1995,270(1):66-72.
    [28]
    Halabian R,Roudkenar MH,Esmaeili NS,et al.Establishment of a cell line expressing recombinant factor VII and its subsequent conversion to active form FVIIa through hepsin by genetic engineering method[J].Vox Sang,2009,96(4):309-315.
    [29]
    Xiao W,Li F,Li C,et al.Construction of the expression vector for recombinant human coagulation factor VII[J].Vox Sang,2012,103(Suppl 1):145-145.
    [30]
    Xiao W,Li CQ,Xiao XP,et al.Expression and fast preparation of biologically active recombinant human coagulation factor VII in CHO-K1 cells[J].Genet Mol Res,2013,12(4):6813-6824.
    [31]
    Wajih N,Owen J,Wallin R.Enhanced functional recombinant factor VII production by HEK 293 cells stably transfected with VKORC1 where the gamma-carboxylase inhibitor calumenin is stably suppressed by shRNA transfection[J].Thromb Res,2008,122(3):405-410.
    [32]
    Mirzaahmadi S,Asaadi-Tehrani G,Bandehpour M,et al.Expression of recombinant human coagulation factor VII by the lizard Leishmania expression system[J].J Biomed Biotechnol,2011,2011:873-874.
    [33]
    Masroori N, Halabian R, Mohammadipour M, et al. High-level expression of functional recombinant human coagulation factor VII in insect cells[J].Biotechnol Lett,2010,32(6):803-809.
    [34]
    Hwang GL,Muller F,Rahman MA,et al.Fish as bioreactors:transgene expression of human coagulation factor VII in fish embryos[J].Mar Biotechnol,2004,6(5):485-492.
    [35]
    Bolt G,Kristensen C,Steenstrup TD.Posttranslational N-glycosylation takes place during the normal processing of human coagulation factor VII[J].Glycobiology,2005,15(5):541-547.
    [36]
    Bolt G,Steenstrup TD,Kristensen C.All post-translational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII[J].Thromb Haemost,2007,98(5):988-997.
    [37]
    Bolt G,Kristensen C,Steenstrup TD.More than one intracellular processing bottleneck delays the secretion of coagulation factor VII[J].Thromb Haemost,2008,100(2):204-210.
    • Related Articles

  • Related Articles

    [1]ZHONG Shuisheng, LUO Zhu, SUN Luning, JANVIER Engelbert Agbokponto, LIANG Maozhi, DING Li. Pharmacokinetic interaction between bencycloquidium bromide nasal spray and budesonide nasal spray in healthy volunteers[J]. Journal of China Pharmaceutical University, 2013, 44(5): 447-450. DOI: 10.11665/j.issn.1000-5048.20130512
    [2]YANG Zhi-xin, WANG Jing, CHEN Zhong-xin, WANG Rui, XIE Li, CHANG Shuang. Comparative study of three pore-forming agents for colon coating solution of 5-aminosalicylic acid[J]. Journal of China Pharmaceutical University, 2012, 43(4): 325-328.
    [3]SONG Yi-ting, ZHOU Hong, SUN Wan-jin, GAO Yuan, LI Chao. Preparation and physicochemical characterization of a spray-dried lornoxicam self-microemulsifying system[J]. Journal of China Pharmaceutical University, 2012, 43(2): 137-141.
    [4]ZHAO Yan-rong, DING Li, RAO Ya-kun, TANG Xiao-wen, DING Jun-hong. Stability and degradation products of otilonium bromide in different media[J]. Journal of China Pharmaceutical University, 2010, 41(6): 548-554.
    [5]CHEN Liang, TONG Xin-yong, SHI Yuan, TAN Yan. Preparation of fluticasone propionate nasal spray and its spray characteristics[J]. Journal of China Pharmaceutical University, 2010, 41(6): 524-528.
    [6]YANG Yan, ZHU Jia-bi, ZHENG Chun-li, CHEN Sheng-jun. Preparation and characterization of aqueous polymer dispersions with high flexibility for coating[J]. Journal of China Pharmaceutical University, 2009, 40(4): 310-315.
    [7]Preparation of Compound Lonicera japonica Effervescent Spray[J]. Journal of China Pharmaceutical University, 2002, (4): 39-41.
    [8]Study onDrug Release Characteristics from Aqueous Ethylcellulose Dispersion Coated Pellets[J]. Journal of China Pharmaceutical University, 2000, (1): 27-30.
    [9]Preparation and Evaluation of Enteric Tablet Erythromycin Coated by Acrylic Resin No.2 Pseudolatex[J]. Journal of China Pharmaceutical University, 1994, (5): 267-270.
    [10]Studies on Aqueous Coating Technique for Acetylsalicylic Acid Enteric Tablets[J]. Journal of China Pharmaceutical University, 1991, (3): 154-157.

  • Cited by

    Periodical cited type(5)

    1. 阿文丽，张衡頔，胡吉蕾，肖春秀，凡蝶，康超，时皎皎，林宁. 姜黄素在低压低氧环境下对机体保护作用机制的研究进展. 中国医药导报. 2024(06): 50-53 .
    2. 郑光艳，吴文丽，刘泽梅，车鑫，王立红. 微流控技术制备槲皮素纳米晶及其大鼠体内药动学研究. 中国医药工业杂志. 2024(04): 519-526 .
    3. 陈榕，颜烨，何梓炫，黄小红，林昭妍. 提升姜黄素疗效的策略及技术研究进展. 中草药. 2024(15): 5315-5330 .
    4. 李双霞，薛晶晶. 浅谈浸出制剂的技术难点与研发策略. 基层中医药. 2023(02): 70-74 .
    5. 王培，牛丽丽，李静宇，耿红梅. 医用多孔支架材料的制备及缓释性能分析. 中国塑料. 2022(11): 73-78 .

    Other cited types(3)

Catalog

    Get Citation
    PDF
    XML
    Article views (1081) PDF downloads (2564) Cited by(8)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：311885

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return